常山药业(300255.SZ)：预计2025年净亏损1.90亿元～2.85亿元

Group 1 - The core viewpoint of the article is that Changshan Pharmaceutical (300255.SZ) is forecasting a significant loss for the fiscal year 2025, with net profit attributable to shareholders expected to be between a loss of 190 million to 285 million yuan, compared to a loss of 249 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses is projected to be a loss of 191 million to 286 million yuan, which is consistent with the previous year's loss of 286 million yuan [1] - The primary reasons for the company's losses include intensified competition in the heparin drug industry, a decline in revenue from core heparin product series, and the impact of centralized procurement and fluctuations in raw material prices, which have kept the gross profit margin at a low level [1]